Things You Should Know

What does women’s cardiovascular health include?

Women’s cardiovascular health refers to the condition of the heart and blood vessels across female life stages, especially during reproductive aging. In this context, cardiovascular disease (CVD) includes disorders such as coronary heart disease, stroke, peripheral arterial disease, deep vein thrombosis, and pulmonary embolism. The topic also includes earlier markers of risk, not only clinical events.

Human longitudinal research has examined subclinical measures such as carotid intima-media thickness (CIMT), a neck artery ultrasound marker of atherosclerosis, alongside systolic blood pressure (SBP), diastolic blood pressure (DBP), non-high-density lipoprotein cholesterol, triglycerides, fasting glucose, body fat, lean mass, and C-reactive protein (CRP). These measures matter because cardiovascular decline often develops gradually over many years before symptoms appear.

For longevity, this topic is not only about avoiding a heart attack in later life. It is about preserving vascular function, metabolic stability, and physical resilience through midlife and older age. Available human evidence suggests that women’s cardiovascular risk is shaped by general factors such as smoking, blood pressure, diabetes, and body mass index (BMI), but also by female-specific factors including age at menarche, age at menopause, menopause type, and the timing of hormonal change.

Why does menopause change heart risk patterns?

Menopause is the end of menstrual cycling and a major hormonal transition, not merely a calendar event. Scientific literature suggests that cardiovascular risk often rises across and after this transition. One proposed reason is the decline in estrogens, especially estradiol (E2), alongside rising follicle-stimulating hormone (FSH). Mechanistic evidence and human observational data suggest these shifts may influence lipid handling, vascular tone, body fat distribution, insulin sensitivity, and blood pressure.

Human studies report that postmenopausal women often show higher low-density lipoprotein cholesterol (LDL-C), triglycerides, central adiposity, and glucose-related risk. A large longitudinal human cohort with repeated measures also found that reproductive age, measured around the final menstrual period (FMP), can be studied separately from chronological age. That matters because part of the cardiovascular shift may relate to menopause itself, not only getting older.

For longevity, this is relevant because midlife changes may influence later risks of stroke, coronary disease, frailty, and loss of function. Still, the evidence is nuanced. Not every observed change is caused only by hormones. Weight gain, smoking, alcohol use, parity, and prior metabolic health may also contribute, so menopause is better understood as a sensitive transition window rather than a single isolated cause.

Which women may have higher lifetime cardiovascular risk?

Some women appear to carry added cardiovascular risk because of their reproductive history. In a large human prospective cohort, shorter reproductive lifespan was categorized as less than 30, 30 to 33, 34 to 37, 38 to 41, or at least 42 years. Reproductive lifespan means the interval between menarche and menopause. In that study, shorter reproductive lifespan and earlier menopause were associated with higher risk of total cardiovascular disease and some stroke outcomes after adjustment for many confounders.

This does not prove that reproductive timing alone causes later disease, but it suggests that these milestones may help identify women who could benefit from earlier risk recognition. Women with premature menopause, often defined as menopause before age 40, and women with surgical menopause are frequently discussed in the evidence base because they may experience a more abrupt loss of ovarian hormone exposure.

This is important for longevity because cardiovascular risk accumulates across decades. A woman may seem healthy in early midlife while still carrying a less favorable long-term pattern. The same studies adjusted for smoking, exercise, diet quality, diabetes, hypertension, hypercholesterolemia, family history, and body mass index (BMI), which shows that reproductive factors add context rather than replacing standard risk factors.

What basic terms help explain this topic?

Several terms make this field easier to understand. Menopausal transition (MT) refers to the years around the final menstrual period (FMP), when cycles become irregular and hormone levels change. Reproductive age means time before or after the final menstrual period, while chronological age means actual age in years. These are related but not identical concepts.

Subclinical atherosclerosis means artery changes that are present before symptoms. A common research marker is carotid intima-media thickness (CIMT), measured by ultrasound. Lipoprotein(a) (Lp(a)) is a cholesterol-related particle associated with atherosclerotic and thrombotic risk, and some evidence suggests its levels may rise after menopause. Dyslipidemia means an unfavorable blood lipid pattern, such as higher low-density lipoprotein cholesterol (LDL-C) or triglycerides.

Menopausal hormone therapy (MHT) refers to estrogen alone or estrogen with a progestin, depending on whether a woman has a uterus. Timing hypothesis means the idea that cardiovascular effects of hormone therapy may differ depending on how soon treatment begins after menopause. In human trials, this remains a qualified concept rather than a universal rule. It is supported more strongly for vascular markers than for hard longevity outcomes such as cardiovascular death.

When is this information most relevant to longevity?

This information becomes especially relevant in midlife, during perimenopause and the years after menopause, but it also matters earlier if a woman has premature menopause, surgical menopause, hypertension, diabetes, or adverse lipid levels. The reason is that longevity is shaped by cumulative exposure to risk, not only by events in old age. Research on aging suggests that cardiovascular health influences later function, frailty, and survival in both sexes, while women have distinct hormonal and reproductive patterns that may modify timing.

Context also matters. In human randomized and observational research on menopausal hormone therapy (MHT), outcomes differed by formulation, age, and time since menopause. For example, some trials examined coronary heart disease (CHD), stroke, venous thromboembolism (VTE), and imaging outcomes such as carotid intima-media thickness (CIMT) or coronary artery calcium. Early postmenopausal initiation has shown more favorable vascular findings in some studies, but late initiation has been associated with harm signals such as venous thromboembolism and stroke.

So, the central longevity lesson is timing and context. Female cardiovascular health is most informative when standard risk factors are interpreted alongside reproductive history, menopausal stage, and the strength and limits of the available human evidence.

Tell Me More

How does menopause interact with weight and glucose regulation?

Human longitudinal cohort evidence suggests menopause interacts with metabolism more than many people assume. In a large study with repeated measures across the final menstrual period (FMP), reproductive age was not strongly linked to faster carotid intima-media thickness (CIMT) progression, but it was associated with modest increases in fat mass and fasting glucose over roughly 4 to 5 years. Those outcomes matter for longevity because adiposity and dysglycemia can accumulate over decades and may raise later risk for type 2 diabetes and vascular disease.

This pattern helps correct a common misconception: menopause does not automatically mean a sudden surge in artery thickening. Instead, the available evidence suggests a subtler shift toward metabolic strain. That distinction matters, because preventing long-term cardiovascular decline may depend as much on preserving body composition and glucose stability as on watching blood pressure alone.

Important limits remain. This cohort mainly included White European women with prior pregnancies, used self-reported final menstrual period timing, and excluded many hormone users, which may bias some estimates toward no effect.

Why do reproductive history and early menopause matter later?

Human prospective cohort evidence indicates that reproductive history may add useful context to standard cardiovascular risk assessment. In one large cohort, reproductive lifespan was grouped as less than 30, 30 to 33, 34 to 37, 38 to 41, or at least 42 years. Analyses reported age-adjusted and multivariable-adjusted relative risk with 95% confidence intervals for total cardiovascular disease (CVD), ischemic stroke, and hemorrhagic stroke. Shorter reproductive lifespan and earlier menopause were associated with higher cardiovascular risk after accounting for smoking, exercise, diet quality, alcohol intake, body mass index (BMI), diabetes, hypertension, and hypercholesterolemia.

For longevity, the implication is not that reproductive timing determines fate. Rather, it may mark cumulative hormonal and metabolic exposure across life. This is especially relevant in women with premature menopause or surgical menopause, where risk may emerge earlier and persist longer.

A useful correction is that reproductive factors do not replace conventional risk factors. They refine them. The evidence is associative, not definitive proof of causation, even after extensive adjustment for confounders.

What has newer research changed about hormone therapy and heart health?

Recent interpretation of the scientific literature has become more specific about timing, formulation, and outcomes. Human randomized trial evidence from the Early Versus Late Intervention Trial (ELITE) enrolled 643 healthy postmenopausal women in early, less than 6 years since menopause, or late, at least 10 years since menopause, groups. The primary outcome was rate of change in carotid intima-media thickness (CIMT). Estradiol lowered CIMT progression in the early group but not in the late group. In related Women’s Health Initiative (WHI) analyses, women aged 50 to 59 showed lower coronary artery calcium (CAC) values with estrogen, while late initiation did not show the same pattern.

This does not mean hormone therapy has established longevity benefits. The stronger evidence supports imaging markers and subgroup differences, not confirmed reductions in cardiovascular death across all women. The longevity assumption comes from the idea that slower atherosclerotic change may support healthier aging, but that link remains indirect in this literature.

The review literature also notes gaps: few prospective trials test long-term duration, and hard event outcomes remain less certain than vascular markers.

Is hormone therapy either safe or unsafe for all women?

No. That all-or-nothing view is one of the biggest misconceptions. Human randomized trial evidence and review evidence both suggest that effects differ by age, time since menopause, and regimen. In the Women’s Health Initiative (WHI) trial of estrogen plus progestin, major outcomes included coronary heart disease (CHD), stroke, venous thromboembolism (VTE), pulmonary embolism (PE), fracture, cancer, and death through a global index. In broader evidence reviews, starting menopausal hormone treatment (MHT) more than 10 years after menopause, or in women with established vascular disease, was linked to early harm signals including VTE, stroke, and recurrent cardiovascular events.

By contrast, earlier use after menopause has shown more favorable vascular findings in some populations. Still, benefit is not uniform, and the addition of medroxyprogesterone acetate (MPA) may lessen estrogen’s vascular advantages. That is why medication effects cannot be judged in the abstract.

For longevity, the trade-off is clear: a therapy may improve some intermediate outcomes while also raising clot or stroke risk in certain settings. The evidence supports individualized clinical evaluation rather than broad claims.

Level Up

Why does timing change estrogen’s vascular effect?

The main theory is that estrogen acts differently in a relatively healthy artery than in one with established plaque. Mechanistic evidence summarized in review literature suggests estrogen may support endothelial-dependent vasodilation, reduce monocyte adhesion to the vessel wall, improve lipid handling, and limit steps involved in atherogenesis. In simple terms, it may help preserve vessel function earlier, but it does not appear to remove advanced plaque once structural disease is present.

Human randomized evidence supports this pattern more strongly for vascular markers than for hard events. In the Early Versus Late Intervention Trial (ELITE), 643 healthy postmenopausal women were grouped by time since menopause, less than 6 years or at least 10 years. The primary outcome was rate of change in carotid intima-media thickness (CIMT) over follow-up. Estradiol was associated with slower carotid intima-media thickness (CIMT) progression only in the early group. In age-stratified analyses from the Women’s Health Initiative (WHI), coronary artery calcium (CAC) was also lower in younger women receiving estrogen.

For longevity, this suggests that vascular aging may depend on biological timing, not only chronological age. Still, caution is needed. Human trials have not yet established that these imaging changes consistently translate into fewer myocardial infarctions or longer survival across all groups.

Could rising FSH shape risk beyond low estrogen?

Possibly. A more advanced view of menopause-related cardiovascular change is that falling estrogen is not the whole story. Review evidence cites human and mechanistic studies linking higher follicle-stimulating hormone (FSH) after menopause with hepatic cholesterol synthesis and less favorable lipid patterns. That raises the idea that the menopausal transition may involve an active endocrine shift, not simply hormone loss.

This matters because it may help explain why some women show lipid worsening even when age alone does not fully account for the change. Research summarized in the scientific literature notes links between follicle-stimulating hormone (FSH) and dyslipidemia, while other human cohort work suggests reproductive age may modestly increase adiposity and fasting glucose without clearly accelerating carotid intima-media thickness (CIMT). Together, these findings support a model in which metabolic strain may be more responsive to menopausal biology than large-artery thickening in the short term.

The evidence remains uneven. Much of this idea rests on mechanistic reasoning and association, not direct proof that follicle-stimulating hormone (FSH) independently drives later cardiovascular events. For longevity research, it is best seen as a promising explanatory pathway that may refine future risk assessment, especially around midlife metabolic change.

Why might exercise help without changing FMD?

This is a useful example of why one marker cannot stand in for the whole cardiovascular system. In an in vivo human intervention study, 11 healthy women more than 10 years past menopause completed 8 weeks of supervised aerobic high-intensity cycling. Primary and related outcomes included maximal oxygen uptake (VO2max), popliteal artery flow-mediated dilation (FMD), body composition, blood lipids, blood pressure, exercise blood flow, and muscle protein expression before and after training.

The study found improved maximal oxygen uptake (VO2max), a better cardiovascular risk profile, lower fat mass, higher high-density lipoprotein (HDL), and changes in proteins linked to vascular signaling, including estrogen-related receptor alpha (ERRα) and endothelial nitric oxide synthase (eNOS). Yet flow-mediated dilation (FMD), which reflects conduit artery endothelial function, did not improve in parallel. That suggests central fitness, muscle-level vascular adaptation, and artery-wall responsiveness may adapt on different timelines or may depend on different biological conditions.

For longevity, this means preserved function may come from several layers of adaptation, not one test result. The evidence is still preliminary here because the sample was small, the intervention lasted 8 weeks, and participants were a specific group of healthy late postmenopausal women.

What may change women’s heart care in the next decade?

The field may move toward a more layered model of cardiovascular aging in women. Instead of treating menopause as a single risk label, future practice may integrate reproductive timing, age at natural menopause (ANM), premature or surgical menopause history, metabolic response during the menopausal transition, and vascular imaging markers such as carotid intima-media thickness (CIMT) or coronary artery calcium (CAC). Review evidence already suggests that menopausal age can matter as much as chronological age when interpreting hormone-related effects.

Human cohort and review data also point toward a more selective use of mechanisms. For example, follicle-stimulating hormone (FSH), lipoprotein(a) (Lp(a)), and body-composition change may help explain why risk rises differently across women. At the same time, randomized and observational evidence indicates that formulation and timing of menopausal hormone treatment (MHT) affect benefit and harm profiles, including venous thromboembolism (VTE) and stroke risk. That may encourage more precise stratification rather than broad yes-or-no views.

The main limitation is that several promising ideas remain ahead of outcome proof. Imaging markers, endocrine pathways, and short-term physiological gains may support healthier aging, but they are not identical to proven extension of lifespan. The most likely shift is toward more individualized prevention that protects present quality of life without ignoring long-term trade-offs.

Pros and Cons

Pros

• Early risk recognition
  ‍Human cohort and review evidence suggests menopause history can refine cardiovascular risk assessment. Earlier recognition of blood pressure, lipid, glucose, and weight changes may support healthier aging before clinical events appear.

• Timed MHT may aid vessels
  ‍Human randomized and review evidence suggests menopausal hormone therapy started within about 5 to 10 years after menopause may slow subclinical vascular change, such as CIMT progression, more than later initiation.

• Metabolic support in some women
  ‍Human studies summarized in reviews suggest MHT may improve lipid patterns, abdominal fat, and fasting glucose in some peri- and postmenopausal women, which may support long-term cardiovascular resilience.

• Exercise improves capacity
  ‍In a small in vivo human training study, 8 weeks of supervised high-intensity aerobic exercise improved VO2max, HDL, fat mass, and estimated 10-year risk in older postmenopausal women, despite no FMD gain.

• Reproductive history adds context
  ‍Human prospective cohort evidence suggests early menopause or a shorter reproductive lifespan is associated with higher later cardiovascular risk. This may help identify women who need earlier preventive follow-up for longevity.

Cons

• Clot and stroke trade-off
  ‍Human trial and review evidence suggests some hormone regimens, especially with later initiation, are associated with higher venous thromboembolism and stroke risk. Risk appears to vary by timing, dose, and formulation.

• Late MHT may not help
  ‍Human randomized evidence suggests starting hormone therapy 10 or more years after menopause may not provide cardioprotection and may expose women to harm without clear vascular benefit.

• Progestin may blunt benefit
  ‍Review evidence suggests adding medroxyprogesterone acetate may reduce estrogen’s vascular advantages compared with estrogen alone, making regimen choice a meaningful trade-off in women with an intact uterus.

• Hard outcomes still mixed
  ‍Available human evidence is stronger for imaging markers such as CIMT or CAC than for confirmed reductions in myocardial infarction, cardiovascular death, or total longevity across all postmenopausal women.

• Exercise evidence is narrow
  ‍The exercise findings come from a small in vivo human study of healthy, sedentary women more than 10 years past menopause. Results may not generalize to women with frailty, disease, or different training tolerance.

Considerations

• Timing shapes effect
  ‍Human evidence supports the timing hypothesis more clearly for vascular markers than for hard events. Menopausal stage and years since the final menstrual period may change benefit and harm patterns.

• Chronological age differs
  ‍Research distinguishes chronological age from reproductive age. Some midlife cardiovascular changes may reflect menopausal timing rather than aging alone, but smoking, BMI, alcohol use, and parity also matter.

• Early menopause risk
  ‍Premature menopause, surgical menopause, and shorter reproductive lifespan are associated with higher long-term cardiovascular risk in cohort studies. These factors add context rather than replacing standard risk markers.

• Route and dose matter
  ‍Review evidence suggests oral and transdermal hormone therapy may differ in triglyceride and clotting effects. Dose, formulation, and progesterone type remain relevant sources of uncertainty in long-term use.

• Evidence gaps remain
  ‍Long-term prospective trials on how long to continue MHT, which regimens are safest, and whether imaging improvements translate into fewer events are still limited in the scientific literature.

Actionable Intelligence

Innovative Tips

• FSH-Lipid Tracking
  ‍Human/mechanistic: 6-12 month FSH+lipid trend review is being studied; benefit remains unproven.
  ‍
• Lp(a) Menopause Check
  Human observational: one-time Lp(a) near menopause is explored; value may vary by baseline risk.
  ‍
• CIMT Timing Window
  ‍Human RCT/cohort: CIMT every few years in select cases is studied; outcome value is still indirect.
  ‍
• VO2max Focus Block
  ‍Small human trial: 8-week interval blocks improved fitness; vascular benefit was not established.
  ‍
• DXA Fat Shift Scan
  ‍Human cohort: DXA over 1-2 years may reveal central fat shift; longevity impact is inferential.
  ‍
• Glucose Drift Mapping
  ‍Human cohort: fasting glucose trends across 4-12 months may show subtle drift; not diagnostic alone.
  ‍
• Early-Menopause Flag
  ‍Human cohort: lifespan under 30 years or menopause before 40 marks higher risk association.
  ‍
• Hormone Timing Review
  ‍Human RCT/review: within 5-10 years postmenopause is studied; clot-stroke tradeoffs remain.
  ‍
• Estradiol Route Note
  ‍Human review: oral vs transdermal effects may differ over months; regimen risks remain context-bound.
  ‍
• Multi-Marker Midlife Log
  ‍Human evidence: annual BP, lipids, waist, glucose logging may refine risk context during transition.

Convergent and Divergent Viewpoints

Convergents

• Earlier menopause marks higher lifetime risk
  ‍Human cohort evidence: menopause before ~40 and shorter reproductive span are linked with higher later CVD risk, relevant to longevity risk stratification.

• Menopause often shifts metabolic risk more than artery thickness
  ‍Human longitudinal evidence: transition years are more consistently linked to modest rises in fat mass and fasting glucose than to faster CIMT progression.

• Standard risk factors still anchor prevention
  ‍Consensus from cohorts and reviews: BP, smoking, diabetes, lipids, BMI, and activity remain central; reproductive history adds context, not replacement.

• Reproductive and chronological age are not identical
  ‍Human longitudinal studies distinguish years since final menstrual period from age in years; both inform midlife cardiovascular aging and longevity.

• Early hormone timing shows stronger vascular signals
  ‍Human RCT and re-analysed trial evidence: starting estrogen within ~5–10 years after menopause shows more favorable CIMT or CAC findings than later starts.

• Late hormone initiation carries early vascular harm signals
  ‍Human RCT evidence: starting HT ≥10 years after menopause has been associated with early VTE, stroke, or recurrent event risk, with little cardioprotection.

• Evidence is stronger for surrogate vascular markers than hard events
  ‍Consensus across trials and reviews: support is firmer for CIMT and CAC changes than for fewer MI, CVD deaths, or longer lifespan.

• Premature or surgical menopause deserves closer cardiovascular attention
  ‍Human cohort and review evidence: abrupt or early ovarian hormone loss is associated with higher long-term CVD risk and may justify earlier monitoring.

• Mechanisms are plausible but not equal to outcome proof
  ‍Reviews agree estrogen may affect lipids, endothelial tone, and atherogenesis, but mechanistic plausibility alone does not establish longer life or fewer events.

Divergent

• Does menopause itself accelerate atherosclerosis?
  ‍Some researchers argue menopause independently hastens artery disease; others say age explains most CIMT change, with menopause acting more through adiposity and glucose.

• How much cardioprotection hormone therapy truly provides
  ‍Some researchers interpret early-start HT as cardioprotective; others view benefits as limited to surrogate markers because event reduction remains unconfirmed.

• Best formulation for cardiovascular trade-offs
  ‍Some researchers favor transdermal estradiol with micronized progesterone for lower clot risk; others say comparative outcome data remain too limited for firm ranking.

• How long hormone therapy can be continued safely
  ‍Some researchers support longer supervised use beyond ~5 years in selected women; others favor shorter duration because long-term cardiovascular and cancer trade-offs remain uncertain.

• Role of progestin class in vascular outcomes
  ‍Some researchers argue medroxyprogesterone acetate may blunt estrogen benefit more than other regimens; others say head-to-head cardiovascular evidence is still sparse.

• Whether imaging-guided hormone decisions improve outcomes
  ‍Some researchers support using CAC or CIMT to refine risk before or during HT; others say outcome evidence is too indirect for routine use.

• How clinically meaningful FSH is as a risk driver
  ‍Some researchers argue rising FSH actively worsens lipids via hepatic pathways; others see FSH mainly as a marker of transition, not a proven causal driver.

• Net value of hormone therapy for longevity
  ‍Some researchers see early HT as potentially supporting healthier vascular aging; others caution that clot, stroke, and cancer trade-offs weaken any longevity inference.

Longevity Index

60/100

_Definition

• Cardiovascular disease (CVD)
  ‍A broad group of disorders affecting the heart and blood vessels. In this context, it includes coronary heart disease, stroke, peripheral arterial disease, deep vein thrombosis, and pulmonary embolism.

• Coronary heart disease (CHD)
  ‍Disease caused by reduced blood flow in the arteries that supply the heart, usually because of atherosclerotic plaque buildup.

• Stroke
  ‍A condition in which blood flow to part of the brain is interrupted or a brain blood vessel bleeds, causing brain injury.

• Ischemic stroke
  ‍A stroke caused by blockage of a blood vessel supplying the brain.

• Hemorrhagic stroke
  ‍A stroke caused by bleeding into or around the brain.

• Peripheral arterial disease

A circulation disorder in which narrowed arteries reduce blood flow to the limbs, usually the legs.

• Deep vein thrombosis
  ‍A blood clot that forms in a deep vein, usually in the leg.

• Pulmonary embolism (PE)
  ‍A blockage in an artery of the lungs, usually caused by a blood clot that traveled from a deep vein.

• Venous thromboembolism (VTE)
  ‍A term that includes both deep vein thrombosis and pulmonary embolism, meaning blood clots that form in the veins and may travel to the lungs.

• Subclinical
  ‍Present but not yet causing obvious symptoms or clinical events.

• Subclinical atherosclerosis
  ‍Early artery-wall changes caused by plaque buildup that are detectable with tests before symptoms develop.

• Atherosclerosis
  ‍A process in which fats, cholesterol, inflammatory material, and other substances build up in artery walls, forming plaque and narrowing the arteries.

• Carotid intima-media thickness (CIMT)
  ‍An ultrasound measurement of the thickness of the inner layers of the carotid artery in the neck. It is used as a research marker of subclinical atherosclerosis and vascular aging.

• Coronary artery calcium (CAC)
  ‍Calcium buildup in the coronary arteries, usually measured by CT imaging, used as a marker of atherosclerotic plaque burden.

• Systolic blood pressure (SBP)
  ‍The top blood pressure number, representing pressure in the arteries when the heart contracts.

• Diastolic blood pressure (DBP)
  ‍The bottom blood pressure number, representing pressure in the arteries when the heart relaxes between beats.

• Non-high-density lipoprotein cholesterol
  ‍The total amount of cholesterol carried by potentially harmful lipoproteins, calculated as total cholesterol minus HDL cholesterol.

• Triglycerides
  ‍A type of fat in the blood that can rise with metabolic dysfunction and is linked to cardiovascular risk when elevated.

• Fasting glucose
  ‍Blood sugar measured after not eating for a period, commonly used to assess glucose regulation and diabetes risk.

• C-reactive protein (CRP)
  ‍A blood marker of inflammation that is sometimes used in cardiovascular risk research.

• Body mass index (BMI)
  ‍A weight-for-height measure used to estimate body size, calculated as weight in kilograms divided by height in meters squared.

• Lean mass
  ‍Body mass excluding fat, including muscle, bone, organs, and body water.

• Adiposity
  ‍The amount or distribution of body fat.

• Central adiposity
  ‍Fat accumulation around the abdomen and internal organs, often associated with higher cardiometabolic risk.

• Body composition

The proportions of fat mass and lean mass in the body.

• Dysglycemia
  ‍Abnormal blood glucose regulation, including higher-than-normal glucose levels that may not yet meet diabetes criteria.

• Type 2 diabetes
  ‍A chronic metabolic disease characterized by elevated blood glucose due to insulin resistance and impaired insulin function.

• Insulin sensitivity
  ‍How effectively the body’s tissues respond to insulin and take up glucose from the bloodstream.

• Insulin resistance
  ‍A state in which the body’s cells respond less effectively to insulin, often leading to higher blood glucose.

• Metabolic stability
  ‍A general term for maintaining healthy regulation of glucose, lipids, body composition, and related metabolic processes.

• Dyslipidemia
  ‍An unfavorable pattern of blood lipids, such as high LDL cholesterol, high triglycerides, or low HDL cholesterol.

• Low-density lipoprotein cholesterol (LDL-C)
  ‍Often called “bad” cholesterol because higher levels are associated with plaque buildup in arteries.

• High-density lipoprotein (HDL)
  ‍A lipoprotein often called “good” cholesterol because it helps transport cholesterol away from tissues and arteries.

• Hypercholesterolemia
  ‍Higher-than-normal cholesterol levels in the blood.

• Lipoprotein(a) (Lp(a))
  ‍A cholesterol-related particle in the blood associated with higher atherosclerotic and thrombotic risk.

• Thrombotic risk
  ‍The likelihood of developing harmful blood clots.

• Vascular tone
  ‍The degree of constriction or relaxation in blood vessel walls, which influences blood flow and blood pressure.

• Vascular function
  ‍How well blood vessels regulate blood flow, pressure, and response to physiologic demands.

• Endothelial
  ‍Relating to the endothelium, the thin inner lining of blood vessels.

• Endothelial-dependent vasodilation
  ‍Widening of blood vessels that depends on healthy function of the endothelium.

• Flow-mediated dilation (FMD)
  ‍A test of endothelial function that measures how much an artery widens in response to increased blood flow.

• Conduit artery
  ‍A larger artery that mainly carries blood to tissues rather than exchanging nutrients directly.

• Atherogenesis
  ‍The biological process by which atherosclerotic plaque forms and develops in artery walls.

• Plaque
  ‍A buildup of fat, cholesterol, calcium, and inflammatory material within an artery wall.

• Monocyte adhesion
  ‍The attachment of a type of immune cell, the monocyte, to the blood vessel wall, an early step in atherosclerosis.

• Menarche
  ‍The first menstrual period.

• Menopause
  ‍The permanent end of menstrual cycling, usually confirmed after 12 months without a menstrual period.

• Postmenopausal
  ‍Referring to the time after menopause has occurred.

• Perimenopause
  ‍The transitional period around menopause when menstrual cycles become irregular and hormone levels fluctuate.

• Menopausal transition (MT)
  ‍The years around the final menstrual period when cycles become irregular and reproductive hormones change.

• Final menstrual period (FMP)
  ‍The last menstrual period, identified retrospectively after 12 months without another period.

• Reproductive age
  ‍A measure of time in relation to the final menstrual period, meaning before or after menopause-related reproductive transition, rather than age in years.

• Chronological age
  ‍Actual age measured in years.

• Reproductive lifespan
  ‍The interval between menarche and menopause.

• Premature menopause
  ‍Menopause occurring before age 40.

• Natural menopause
  ‍Menopause that occurs without surgery or other medical intervention stopping ovarian function.

• Age at natural menopause (ANM)
  ‍The age at which natural menopause occurs.

• Surgical menopause
  ‍Menopause caused by surgical removal of the ovaries or surgery that ends ovarian hormone production.

• Parity
  ‍The number of pregnancies carried to a viable gestational age; in research, it is used as part of reproductive history.

• Estradiol (E2)
  ‍The main estrogen hormone during reproductive years, involved in menstrual cycling, vascular biology, and metabolism.

• Estrogens
  ‍A group of female sex hormones that influence reproduction, metabolism, bone, and blood vessel function.

• Follicle-stimulating hormone (FSH)
  ‍A hormone involved in ovarian function that typically rises after menopause as ovarian hormone production declines.

• Endocrine shift
  ‍A change in hormone patterns and signaling across a life stage such as menopause.

• Hepatic cholesterol synthesis
  ‍Production of cholesterol by the liver.

• Menopausal hormone therapy (MHT)
  ‍Treatment with estrogen alone or estrogen plus a progestin, used around or after menopause depending on whether a woman has a uterus.

• Hormone therapy (HT)
  ‍A general term for treatment using hormones; in this context, it refers to menopausal hormone therapy.

• Progestin
  ‍A synthetic hormone with progesterone-like effects, often added to estrogen therapy in women with a uterus.

• Medroxyprogesterone acetate (MPA)
  ‍A specific synthetic progestin used in some menopausal hormone therapy regimens.

• Timing hypothesis
  ‍The idea that the cardiovascular effects of menopausal hormone therapy may depend on how soon treatment is started after menopause.

• Formulation
  ‍The specific composition of a therapy, such as which hormone is used and in what combination.

• Transdermal
  ‍Delivered through the skin, such as by patch, gel, or spray.

• Oral
  ‍Taken by mouth.

• Randomized trial
  ‍A study in which participants are assigned by chance to different treatments or comparison groups to reduce bias.

• Observational study
  ‍A study in which researchers observe associations without assigning treatments.

• Prospective cohort
  ‍A study that follows a group of people forward in time to examine how exposures relate to later outcomes.

• Longitudinal study
  ‍A study that repeatedly measures the same participants over time.

• Repeated measures
  ‍Multiple measurements taken from the same person across different time points.

• Multivariable-adjusted
  ‍Statistically adjusted for several measured factors at once to reduce confounding.

• Relative risk
  ‍A comparison of risk between two groups, showing how much more or less likely an outcome is in one group than another.

• 95% confidence interval
  ‍A statistical range that reflects the uncertainty around an estimate; in repeated sampling, the true value would be expected to fall within this range about 95% of the time.

• Confounders
  ‍Factors that can distort the apparent relationship between an exposure and an outcome because they are related to both.

• Association
  ‍A relationship between two variables observed in data, which does not by itself prove causation.

• Causation
  ‍A direct cause-and-effect relationship in which one factor produces a change in another.

• Mechanistic evidence
  ‍Evidence about the biological processes through which a factor might influence an outcome.

• Hard outcomes
  ‍Major clinical outcomes such as heart attack, stroke, cardiovascular death, or total mortality, rather than intermediate test results.

• Surrogate marker
  ‍An indirect measure, such as an imaging or laboratory value, used to estimate disease risk or treatment effect instead of measuring major clinical outcomes directly.

• Myocardial infarction
  ‍A heart attack caused by blocked blood flow to part of the heart muscle.

• Frailty
  ‍A state of reduced physiologic reserve and increased vulnerability to stressors, common in aging research.

• Physical resilience
  ‍The ability to maintain or recover physical function when facing illness, stress, or aging-related challenges.

• VO2max
  ‍Maximal oxygen uptake during intense exercise, a standard measure of cardiorespiratory fitness.

• Popliteal artery
  ‍An artery located behind the knee.

• In vivo
  ‍Studied in a living organism rather than in isolated tissues or laboratory systems.

• Endothelial nitric oxide synthase (eNOS)
  ‍An enzyme in endothelial cells that helps produce nitric oxide, a molecule important for blood vessel relaxation.

• Estrogen-related receptor alpha (ERRα)
  ‍A protein involved in energy metabolism and cellular regulation that is studied in relation to exercise and vascular signaling.

• DXA
  ‍Dual-energy X-ray absorptiometry, an imaging method used to measure body composition, including fat and lean mass.

• Early Versus Late Intervention Trial (ELITE)
  ‍A randomized human trial that tested whether estradiol’s vascular effects differed when treatment was started early versus late after menopause.

• Women’s Health Initiative (WHI)
  ‍A large U.S. research program that included major randomized trials and observational studies on hormone therapy and chronic disease outcomes in postmenopausal women.

• Global index
  ‍A combined outcome measure used in some trials to summarize overall balance of benefits and harms across multiple major events.

‍